These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33128207)

  • 1. Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.
    Lawson R; Staatz CE; Fraser CJ; Hennig S
    Clin Pharmacokinet; 2021 Jan; 60(1):17-51. PubMed ID: 33128207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.
    Sun Y; Huang J; Hao C; Li Z; Liang W; Zhang W; Chen B; Yang W; Hu J
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):293-308. PubMed ID: 31834435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
    Gaziev J; Nguyen L; Puozzo C; Mozzi AF; Casella M; Perrone Donnorso M; Gravina P; Sodani P; Marziali M; Isgrò A; Simone MD; Andreani M; Formosa A; Testi M; Federici G; Bernardini S; Lucarelli G
    Blood; 2010 Jun; 115(22):4597-604. PubMed ID: 20237319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
    Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
    Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Choi B; Kim MG; Han N; Kim T; Ji E; Park S; Kim IW; Oh JM
    Pharmacogenomics; 2015; 16(14):1585-94. PubMed ID: 26419450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
    Nava T; Kassir N; Rezgui MA; Uppugunduri CRS; Huezo-Diaz Curtis P; Duval M; Théoret Y; Daudt LE; Litalien C; Ansari M; Krajinovic M; Bittencourt H
    Br J Clin Pharmacol; 2018 Jul; 84(7):1494-1504. PubMed ID: 29469189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
    Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
    J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
    Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
    Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations.
    Takahashi T; Jaber MM; Brown SJ; Al-Kofahi M
    Clin Pharmacokinet; 2023 Jul; 62(7):955-968. PubMed ID: 37415003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance.
    Lawson R; Staatz CE; Fraser CJ; Ramachandran S; Teague L; Mitchell R; O'Brien T; Hennig S
    CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1002-1017. PubMed ID: 35611997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.
    Johnson L; Orchard PJ; Baker KS; Brundage R; Cao Q; Wang X; Langer E; Farag-El Maasah S; Ross JA; Remmel R; Jacobson PA
    J Clin Pharmacol; 2008 Sep; 48(9):1052-62. PubMed ID: 18635758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations.
    Rosser SPA; Lee S; Kohli S; Keogh SJ; Chung J; O'Brien T; Fraser C; McLachlan AJ; Shaw PJ; Nath CE
    Br J Clin Pharmacol; 2023 Apr; 89(4):1413-1424. PubMed ID: 36369677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
    Almog S; Kurnik D; Shimoni A; Loebstein R; Hassoun E; Gopher A; Halkin H; Nagler A
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):117-23. PubMed ID: 20601034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation.
    Lawson R; Paterson L; Fraser CJ; Hennig S
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):379-391. PubMed ID: 34021809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulfan in hematopoietic stem cell transplant setting.
    McCune JS; Holmberg LA
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):957-69. PubMed ID: 19611402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan.
    Kusama M; Kubota T; Matsukura Y; Matsuno K; Ogawa S; Kanda Y; Iga T
    Clin Chim Acta; 2006 Jun; 368(1-2):93-8. PubMed ID: 16448639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children.
    Nishikawa T; Yamaguchi H; Ikawa K; Nakayama K; Higashi E; Miyahara E; Abematsu T; Nakagawa S; Kodama Y; Tanabe T; Shigemi A; Shinkoda Y; Okamoto Y; Takeda Y; Kawano Y
    Pediatr Int; 2019 Jun; 61(6):558-565. PubMed ID: 30963629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.
    Abbasi N; Vadnais B; Knutson JA; Blough DK; Kelly EJ; O'Donnell PV; Deeg HJ; Pawlikowski MA; Ho RJ; McCune JS
    J Clin Pharmacol; 2011 Oct; 51(10):1429-38. PubMed ID: 21135089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
    Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
    Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
    Elhasid R; Krivoy N; Rowe JM; Sprecher E; Adler L; Elkin H; Efrati E
    Pediatr Blood Cancer; 2010 Dec; 55(6):1172-9. PubMed ID: 20672371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.